Researchers and clinicians refer to outcomes of genomic testing that extend beyond clinical
utility as 'personal utility'. No systematic delineation of personal utility exists, making it …

With the rapid evolution of next-generation DNA sequencing technologies, the cost of
sequencing a human genome has plummeted, and genomics has started to pervade health …

Whole-genome sequencing (WGS) is positioned to become one of the most robust
strategies for achieving timely diagnosis of rare genomic diseases. Despite its favorable …

Despite rapid technical progress and demonstrable effectiveness for some types of
diagnosis and therapy, much remains to be learned about clinical genome and exome …

Given the limited therapeutic options for most rare diseases diagnosed through genomic
sequencing (GS) and the proportion of patients who remain undiagnosed even after GS, it is …

Abstract Background and Objectives Successful clinical integration of genomic sequencing
(GS) requires evidence of its utility. While GS potentially has benefits (utilities) or harms …

Background Individual genome sequencing results are valued by patients in ways distinct
from clinical utility. Such outcomes have been described as components of “personal utility,” …

In genomics, perceived and personal utility have been proposed as constructs of value that
include the subjective meanings and uses of genetic testing. Precisely what constitutes …

Precision medicine (PM) can be defined as a predictive, preventive, personalized, and
participatory healthcare service delivery model. Recent developments in molecular biology …

There is growing impetus to include measures of personal utility, the nonmedical value of
information, in addition to clinical utility in health technology assessment (HTA) of genomic …